Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 PHASE 2A STUDY OF CTEV IN CORONARY ARTERY BYPASS GRAFTING (CABG) IS EXPECTED TO START THIS QUARTER   PROGRESSION OF CTEV INTO HUMAN STUDY SUPPORTED BY POSITIVE PRECLINICAL RESULTS PRESENTED AT MULTIPLE SCIENTIFIC MEETINGS AND IN A RECENT PUBLICATION  DURHAM, N.C., JULY 27, 2026 (GLOBE NEWSWIRE) -- HUMACYTE, INC. (NASDAQ: HUMA), A CLINICAL-STAGE BIOTECHNOLOGY PLATFORM COMPANY DEVELOPING UNIVERSALLY IMPLANTABLE, BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, ANNOUNCED THAT THE FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR A FIRST-IN-HUMAN CLINICAL STUDY OF THE CORONARY TISSUE ENGINEERED VESSEL (CTEV) IN CORONARY ARTERY BYPASS GRAFTING (CABG).

HUMACYTE ANNOUNCES FDA ACCEPTANCE OF IND FOR FIRST-IN-HUMAN CLINICAL STUDY OF CTEV FOR CORONARY ARTERY BYPASS GRAFTING

- DR. ROBERT J. KOSSMANN HAS SERVED AS A PROMINENT ADVOCATE FOR KIDNEY DISEASE PATIENTS IN MULTIPLE ROLES INCLUDING EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER FOR FRESENIUS MEDICAL CARE NORTH AMERICA -

HUMACYTE APPOINTS KEY NEPHROLOGISTS AS ADVISORS TO PREPARE FOR PLANNED COMMERCIALIZATION OF THE ATEV IN DIALYSIS ACCESS

 POSITIVE RESULTS FROM THE V012 PHASE 3 STUDY WERE PRESENTED AT THE SOCIETY FOR VASCULAR SURGERY'S VASCULAR ANNUAL MEETING IN BOSTON   WOMEN WHO RECEIVED HUMACYTE'S ATEV EXPERIENCED AN AVERAGE OF THREE MORE MONTHS WITHOUT A DIALYSIS CATHETER THAN WOMEN WHO RECEIVED AV FISTULA, THE CURRENT STANDARD OF CARE   COMPANY TO HOLD INVESTOR EVENT TODAY, JUNE 15 TH , AT 5:00 P.M. ET  DURHAM, N.C.

HUMACYTE'S BIOENGINEERED BLOOD VESSEL OUTPERFORMS THE STANDARD OF CARE FOR WOMEN ON DIALYSIS IN PHASE 3 RESULTS PRESENTED AT THE SOCIETY FOR VASCULAR SURGERY VASCULAR ANNUAL MEETING

DURHAM, N.C., JUNE 10, 2026 (GLOBE NEWSWIRE) -- HUMACYTE, INC. (NASDAQ: HUMA), A COMMERCIAL-STAGE BIOTECHNOLOGY PLATFORM COMPANY DEVELOPING UNIVERSALLY IMPLANTABLE, BIOENGINEERED HUMAN TISSUES AT COMMERCIAL SCALE, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 47,619,048 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $1.05 PER SHARE. THE AGGREGATE GROSS PROCEEDS FROM THIS OFFERING ARE EXPECTED TO BE $50 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY HUMACYTE. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT JUNE 12, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. IN ADDITION, HUMACYTE HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 7,142,857 SHARES OF HUMACYTE'S COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES OF COMMON STOCK ARE BEING SOLD BY HUMACYTE.

HUMACYTE, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

DURHAM, N.C., JUNE 10, 2026 (GLOBE NEWSWIRE) -- HUMACYTE, INC. (NASDAQ: HUMA), A COMMERCIAL-STAGE BIOTECHNOLOGY PLATFORM COMPANY DEVELOPING UNIVERSALLY IMPLANTABLE, BIOENGINEERED HUMAN TISSUES AT COMMERCIAL SCALE, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK. IN ADDITION, HUMACYTE INTENDS TO GRANT THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 15% OF THE NUMBER OF SHARES OF COMMON STOCK SOLD IN CONNECTION WITH THE OFFERING. ALL OF THE SHARES OF COMMON STOCK ARE BEING OFFERED BY HUMACYTE.

HUMACYTE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

- HUMACYTE PLANS TO FILE A SUPPLEMENTAL BIOLOGIC LICENSE APPLICATION (BLA) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) DURING THE SECOND HALF OF 2026 -

HUMACYTE ATEV MET SUPERIORITY PRIMARY ENDPOINT COMPARED TO STANDARD OF CARE AV FISTULA IN INTERIM ANALYSIS OF V012 PHASE 3 STUDY IN FEMALE DIALYSIS ACCESS PATIENTS

SHAREHOLDERS ARE ENCOURAGED TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS AND OPTIONS AT NO COST OR OBLIGATION. WE WOULD HANDLE ANY MATTER ON A CONTINGENT FEE BASIS, WHEREBY YOU WOULD NOT BE RESPONSIBLE FOR OUT-OF-POCKET PAYMENT OF OUR LEGAL FEES OR EXPENSES.

DID HUMACYTE, INC. INSIDERS BREACH THEIR FIDUCIARY DUTIES TO SHAREHOLDERS?

- DIALYSIS ACCESS REQUIRES FREQUENT CANNULATION, OFTEN EXCEEDING 300 NEEDLE PUNCTURES ANNUALLY - - THE ATEV WAS OBSERVED TO MAINTAIN LONG-TERM STRUCTURAL INTEGRITY AND SELF-REPAIR WITH SMOOTH MUSCLE CELL REPOPULATION DESPITE REPEATED CANNULATIONS - - HUMACYTE ANTICIPATES THAT TOP-LINE INTERIM RESULTS FROM ITS ONGOING V012 PHASE 3 STUDY IN DIALYSIS ACCESS WILL BE AVAILABLE FOR REPORTING IN JUNE - DURHAM, N.C., MAY 26, 2026 (GLOBE NEWSWIRE) -- HUMACYTE, INC. (NASDAQ: HUMA), A COMMERCIAL-STAGE BIOTECHNOLOGY PLATFORM COMPANY DEVELOPING UNIVERSALLY IMPLANTABLE, BIOENGINEERED HUMAN TISSUES AT COMMERCIAL SCALE, TODAY ANNOUNCED THE PRESENTATION OF RESEARCH PROVIDING EVIDENCE OF SELF-REPAIR OF THE ACELLULAR TISSUE ENGINEERED VESSEL (ATEV) AFTER CANNULATION FOR DIALYSIS ACCESS AT THE VASCULAR ACCESS SOCIETY OF THE AMERICAS (VASA)2026 VASCULAR ACCESS FOR DIALYSIS SYMPOSIUM IN SALT LAKE CITY, UTAH.

HUMACYTE ANNOUNCES PRESENTATION AT VASA MEETING OF RESEARCH HIGHLIGHTING SELF-REPAIR OF ATEV AFTER CANNULATION FOR DIALYSIS ACCESS

- SURGICAL IMPLANT  NEXT GENERATION CONTRACT MAKES SYMVESS MORE EASILY ACCESSIBLE TO 170 VA HOSPITALS  - SAC AWARDS REQUIRE INTENSIVE PRODUCT AND VALUE ANALYSIS VETTING BY A SURGICAL COMMITTEE AND STREAMLINE THE APPROVAL PROCESS BY INDIVIDUAL HOSPITALS - DURHAM, N.C., MAY 20, 2026 (GLOBE NEWSWIRE) -- HUMACYTE, INC. (NASDAQ: HUMA), A COMMERCIAL-STAGE BIOTECHNOLOGY PLATFORM COMPANY DEVELOPING UNIVERSALLY IMPLANTABLE, BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, ANNOUNCED TODAY THAT SYMVESS IS NOW UNDER CONTRACT WITH THE WITH STRATEGIC ACQUISITION CENTER (SAC) OF THE U.S. DEPARTMENT OF VETERANS AFFAIRS (VA).

HUMACYTE ANNOUNCES SYMVESS IS NOW UNDER CONTRACT WITH THE STRATEGIC ACQUISITION CENTER (SAC) OF THE U.S. DEPARTMENT OF VETERANS AFFAIRS

- APPOINTED JIM MERCADANTE AS CHIEF COMMERCIAL OFFICER AND DR. TODD RASMUSSEN AS CHIEF SURGICAL OFFICER - - FIRST QUARTER SALES OF SYMVESS WERE $0.5 MILLION IN 2026 COMPARED TO $0.1 MILLION IN 2025 - - PURCHASE COMMITMENT RECEIVED FOR A MINIMUM OF $1.475 MILLION FOR A CLINICAL EVALUATION AND OUTREACH PROGRAM IN THE KINGDOM OF SAUDI ARABIA - - ANNOUNCED ISRAELI MINISTRY OF HEALTH ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR SYMVESS FOR VASCULAR INJURY REPAIR - - U.S. DEPARTMENT OF DEFENSE FUNDING FOR PROCUREMENT OF BIOENGINEERED BLOOD VESSELS - - MAJOR MILESTONE UPCOMING: TOP-LINE INTERIM RESULTS FROM V012 PHASE 3 STUDY IN HEMODIALYSIS ACCESS - -CONFERENCE CALL TODAY AT 8:00 AM ET - DURHAM, N.C., MAY 13, 2026 (GLOBE NEWSWIRE) -- HUMACYTE, INC. (NASDAQ: HUMA), A COMMERCIAL-STAGE BIOTECHNOLOGY PLATFORM COMPANY DEVELOPING UNIVERSALLY IMPLANTABLE, BIOENGINEERED HUMAN TISSUES AT COMMERCIAL SCALE, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

Humacyte, Inc.

HUMA

Price

Financial Reports

No items found.

Press Releases

Humacyte, Inc.

HUMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

HUMA